In 2005–06, neomycin was the fifth-most-prevalent allergen in [[patch test]] results (10.0%).<ref>{{cite journal |pmid=19470301 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1710-3568&volume=20&issue=3&spage=149 |year=2009 |author1=Zug |first1=K. A. |title=Patch-test results of the North American Contact Dermatitis Group 2005-2006 |journal=Dermatitis |volume=20 |issue=3 |pages=149–60 |last2=Warshaw |first2=E. M. |last3=Fowler Jr |first3=J. F. |last4=Maibach |first4=H. I. |last5=Belsito |first5=D. L. |last6=Pratt |first6=M. D. |last7=Sasseville |first7=D |last8=Storrs |first8=F. J. |last9=Taylor |first9=J. S. |last10=Mathias |first10=C. G. |last11=Deleo |first11=V. A. |last12=Rietschel |first12=R. L. |last13=Marks |first13=J }}</ref> Neomycin, like other aminoglycosides, has been shown to be ototoxic causing tinnitus, hearing loss, and vestibular problems in a small number of patients. Patients with existing tinnitus or sensorineural hearing loss should speak with their doctor about the risks and side effects prior to taking this medication.  
